FCF co-organized, together with its partner YAFO Capital, the “ACCESS CHINA Biotech Forum” which was held online on June 21st & 24th, 2022. ACCESS CHINA Biotech Forum is a quarterly corporate access event series between … Read more
FCF co-organizes, together with its partner YAFO Capital, the “ACCESS CHINA Biotech Forum” which will be held online on April 18th & 19th, 2022. ACCESS CHINA Biotech Forum is a quarterly corporate access event series … Read more
September 23rd-24th 2021, Suzhou and Online FCF co-organizes, together with its partner YAFO Capital, the ACCESS CHINA Biotech Forum – The largest China oriented healthcare partnering event. We are honored to invite you to our “ACCESS … Read more
On Thursday, June 10, the German newspaper “Handelsblatt” reported online and in its print version on the planned IPO of ATAI Life Sciences, a German company specializing in psychedelic drugs. Previously labeled as narcotic drugs, … Read more
Number of SPAC IPOs has stagnated since April Potential reason could be a Statement from U.S. Securities and Exchange Commission (SEC) 611 SPAC IPOs since May 2020 Munich, May 18, 2021 – The boom around … Read more
Financing volume in the USA doubled in the first quarter of 2021 High growth also in Europe Munich, May 05, 2021 – The boom in biotech venture capital financing continues: In the US, the venture … Read more
Der Boom um Special Purpose Acquisition Companies, auch SPACs genannt, setzt sich 2021 ungebremst fort. Lag die Zahl der SPAC-Börsengänge im gesamten Jahr 2020 noch bei 306 SPAC-IPOs, liegt sie in den ersten drei Monaten … Read more
Der deutsche Markt erlebt hier seinen schonungslosen Moment der Wahrheit Dass die Corona-Krise besondere Entwicklungen mit sich bringt, ist in vielen Bereichen zu spüren. Die Auswirkungen der Ausbreitung des Virus sind in dieser Form noch … Read more
German life science companies must raise more money abroad The fact that Germany’s life sciences industry is doing very well in European comparison is due to a few big deals. The latest venture capital research … Read more
By Dr. Mathias Schott and Sebastian Sommer To start off with the good news, Bavaria has proven its position within the German Biotech scene last year. The Free State accounted for an astonishing 40 percent of the German … Read more
